Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors
Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.
Source: onclive.com
Io 108 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Io 108. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Io 108 Today - Breaking & Trending Today
Taylor Highlights Safety and Efficacy of IgG4 Monoclonal Antibody IO-108 in Advanced Solid Tumors
Matthew H. Taylor, MD, discusses findings from a phase 1 study of IO-108 in advanced solid tumors, which was presented during the 2023 AACR Annual Meeting.
Source: onclive.com
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Source: onclive.com